ADAP
ADAP
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $13.677M ▲ | $41.464M ▼ | $-30.34M ▲ | -221.832% ▲ | $-0.12 ▲ | $-26.257M ▲ |
| Q1-2025 | $7.285M ▲ | $52.139M ▼ | $-47.584M ▲ | -653.178% ▲ | $-0.19 ▲ | $-42.662M ▲ |
| Q4-2024 | $3.222M ▼ | $76.741M ▲ | $-74.215M ▼ | -2.303K% ▼ | $-0.29 ▼ | $-67.974M ▼ |
| Q3-2024 | $40.901M ▼ | $55.581M ▼ | $-17.617M ▼ | -43.072% ▼ | $-0.069 ▼ | $-12.859M ▼ |
| Q2-2024 | $128.231M | $59.531M | $69.521M | 54.215% | $0.27 | $71.015M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $26.061M ▼ | $130.633M ▼ | $201.591M ▲ | $-70.958M ▼ |
| Q1-2025 | $59.563M ▼ | $158.072M ▼ | $195.501M ▼ | $-37.429M ▼ |
| Q4-2024 | $151.605M ▼ | $245.963M ▼ | $234.114M ▼ | $11.849M ▼ |
| Q3-2024 | $186.09M ▼ | $317.436M ▼ | $237.447M ▲ | $79.989M ▼ |
| Q2-2024 | $214.789M | $321.702M | $225.428M | $96.274M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-30.34M ▲ | $-34.78M ▲ | $18.49M ▼ | $1.654M ▲ | $-15.226M ▲ | $-34.855M ▲ |
| Q1-2025 | $-47.584M ▲ | $-66.592M ▼ | $41.154M ▲ | $-25.32M ▼ | $-50.202M ▼ | $-66.592M ▼ |
| Q4-2024 | $-70.814M ▼ | $-34.204M ▲ | $8.167M ▲ | $1K ▼ | $-26.216M ▲ | $-35.377M ▲ |
| Q3-2024 | $-17.617M ▼ | $-54.451M ▼ | $-66.018M ▼ | $25.001M ▲ | $-95.254M ▼ | $-54.886M ▼ |
| Q2-2024 | $69.521M | $0 | $-743K | $24.512M | $71.148M | $46.631M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Development revenue | $40.00M ▲ | $140.00M ▲ | $0 ▼ | $0 ▲ |
 Product revenue net | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
About Adaptimmune Therapeutics plc
https://www.adaptimmune.comAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $13.677M ▲ | $41.464M ▼ | $-30.34M ▲ | -221.832% ▲ | $-0.12 ▲ | $-26.257M ▲ |
| Q1-2025 | $7.285M ▲ | $52.139M ▼ | $-47.584M ▲ | -653.178% ▲ | $-0.19 ▲ | $-42.662M ▲ |
| Q4-2024 | $3.222M ▼ | $76.741M ▲ | $-74.215M ▼ | -2.303K% ▼ | $-0.29 ▼ | $-67.974M ▼ |
| Q3-2024 | $40.901M ▼ | $55.581M ▼ | $-17.617M ▼ | -43.072% ▼ | $-0.069 ▼ | $-12.859M ▼ |
| Q2-2024 | $128.231M | $59.531M | $69.521M | 54.215% | $0.27 | $71.015M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $26.061M ▼ | $130.633M ▼ | $201.591M ▲ | $-70.958M ▼ |
| Q1-2025 | $59.563M ▼ | $158.072M ▼ | $195.501M ▼ | $-37.429M ▼ |
| Q4-2024 | $151.605M ▼ | $245.963M ▼ | $234.114M ▼ | $11.849M ▼ |
| Q3-2024 | $186.09M ▼ | $317.436M ▼ | $237.447M ▲ | $79.989M ▼ |
| Q2-2024 | $214.789M | $321.702M | $225.428M | $96.274M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-30.34M ▲ | $-34.78M ▲ | $18.49M ▼ | $1.654M ▲ | $-15.226M ▲ | $-34.855M ▲ |
| Q1-2025 | $-47.584M ▲ | $-66.592M ▼ | $41.154M ▲ | $-25.32M ▼ | $-50.202M ▼ | $-66.592M ▼ |
| Q4-2024 | $-70.814M ▼ | $-34.204M ▲ | $8.167M ▲ | $1K ▼ | $-26.216M ▲ | $-35.377M ▲ |
| Q3-2024 | $-17.617M ▼ | $-54.451M ▼ | $-66.018M ▼ | $25.001M ▲ | $-95.254M ▼ | $-54.886M ▼ |
| Q2-2024 | $69.521M | $0 | $-743K | $24.512M | $71.148M | $46.631M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
| Development revenue | $40.00M ▲ | $140.00M ▲ | $0 ▼ | $0 ▲ |
| Product revenue net | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
CEO
Adrian G. Rawcliffe
Compensation Summary
(Year 2024)
CEO
Adrian G. Rawcliffe
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Guggenheim
Buy
Scotiabank
Sector Outperform
Wells Fargo
Equal Weight
HC Wainwright & Co.
Neutral
Mizuho
Neutral
Barclays
Underweight
Grade Summary
Price Target
Institutional Ownership
LONG FOCUS CAPITAL MANAGEMENT, LLC
18.578M Shares
$901.024K
UBS GROUP AG
6.667M Shares
$323.367K
RENAISSANCE TECHNOLOGIES LLC
4.054M Shares
$196.623K
MORGAN STANLEY
3.666M Shares
$177.804K
JANE STREET GROUP, LLC
2.805M Shares
$136.059K
ACADIAN ASSET MANAGEMENT LLC
1.485M Shares
$72.03K
BANK OF AMERICA CORP /DE/
1.32M Shares
$64.004K
EMPIRICAL FINANCE, LLC
800K Shares
$38.8K
B. RILEY WEALTH ADVISORS, INC.
500K Shares
$24.25K
RATHBONES GROUP PLC
432.818K Shares
$20.992K
FMR LLC
340.409K Shares
$16.51K
SUSQUEHANNA INTERNATIONAL GROUP, LLP
308.065K Shares
$14.941K
BLACKROCK INC.
193.757K Shares
$9.397K
LUMBARD & KELLNER, LLC
114.264K Shares
$5.542K
LAKERIDGE WEALTH MANAGEMENT LLC
110.4K Shares
$5.354K
XTX TOPCO LTD
102.501K Shares
$4.971K
ACT CAPITAL MANAGEMENT, LLC
90K Shares
$4.365K
CAPTRUST FINANCIAL ADVISORS
79.083K Shares
$3.836K
STATE OF TENNESSEE, TREASURY DEPARTMENT
73.376K Shares
$3.559K
GEODE CAPITAL MANAGEMENT, LLC
67.032K Shares
$3.251K
Summary
Only Showing The Top 20